COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,046 Articles (22,627 medRxiv, 8,419 bioRxiv)

Most recent first Previous |  Page 1407: Articles 14061-14070  | Next

Into the thirteenth Month: A Case Study on the Outbreak Analytics and Modeling the spread of SARS-CoV-2 Infection in Pune City, India
Monteiro, J., Pujari, B., Maitra Bhattacharrya, S., Raghunathan, A., Keskar, A., Shaikh, A., Bogam, P., Kadu, S., Raut, N., Vavale, D., Mishra, R., Kembhavi, A., Shashidhara, L. S., Mave, V.
10.1101/2021.06.22.21259295 — Posted: 2021-06-25
Pulmonary thromboembolism in patients after COVID-19 - predictive indicators for correct diagnosis
Yakova-Hristova, D., Simova, I., Pavlov, P., Hristov, M., Kundurzhiev, T., Dimitrov, N., Vekov, T.
10.1101/2021.06.24.21258842 — Posted: 2021-06-25
Potential environmental transmission routes of SARS-CoV-2 inside a large meat processing plant experiencing COVID-19 clusters
de Rooij, M. M. T., Sikkema, R. S., Bouwknegt, M., de Geus, Y., Stanoeva, K. R., Nieuwenweg, S., van Dam, S., Raben, C., Dohmen, W., Heederik, D., Reusken, C., Meijer, A., Koopmans, M., Franz, E., Smit, L.
10.1101/2021.06.20.21259212 — Posted: 2021-06-25
Susceptibility of zero community transmission regimes to new variants of SARS-CoV-2: a modelling study of Queensland
Sanz-Leon, P., Stevenson, N. J., Stuart, R. M., Abeysuriya, R. G., Pang, J. C., Lambert, S. B., Kerr, C. C., Roberts, J. A.
10.1101/2021.06.08.21258599 — Posted: 2021-06-25
The serological diversity of serum IgG/IgA/IgM against the SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan
Kaneko, Y., Sugiyama, A., Tanaka, T., Fukui, K., Taguchi, A., Nakayama, A., Koga, K., Kishi, Y., Daming, W., Qian, C., Xia, F., He, F., Zheng, L., Yu, Y., Wada, Y., Wada, Y., Kodama, T., Kawamura, T.
10.1101/2021.06.17.21258858 — Posted: 2021-06-25
Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021
Budziar, W., Gembara, K., Szymczak, A., Jedruchniewicz, N., Baniecki, K., Pikies, A., Nahorecki, A., Hoffmann, A., Kardas, A., Klimek, T., Kazmierczak, Z., Witkiewicz, W., Barczyk, K., Dabrowska, K.
10.1101/2021.06.22.21258711 — Posted: 2021-06-25
Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection
Schultz, D., Johnson, R., Ayyanathan, K., Miller, J., Whig, K., Kamalia, B., Dittmar, M., Weston, S., Hammond, H., Dillen, C., Castellana, L., Lee, J. S., Li, M., Lee, E. M., Constant, S., Ferrer, M., Thaiss, C., Frieman, M., Cherry, S.
10.1101/2021.06.24.449811 — Posted: 2021-06-24
Integrative COVID-19 Biological Network Inference with Probabilistic Core Decomposition
Guo, Y., Esfahani, F., Shao, X., Srinivasan, V., Thomo, A., Xing, L., Zhang, X.
10.1101/2021.06.23.449535 — Posted: 2021-06-24
E484K and N501Y SARS-CoV 2 Spike Mutants Increase ACE2 Recognition but Reduce Affinity for Neutralizing Antibody
Chakraborty, S.
10.1101/2021.06.23.449627 — Posted: 2021-06-24
Structure, activity and inhibition of human TMPRSS2, a protease implicated in SARS-CoV-2 activation
Fraser, B. J., Beldar, S., Seitova, A., Hutchinson, A., Mannar, D., Li, Y., Kwon, D., Tan, R., Wilson, R. P., Leopold, K., Subramaniam, S., Halabelian, L., Arrowsmith, C. H., Benard, F.
10.1101/2021.06.23.449282 — Posted: 2021-06-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).